News

Senores Pharmaceuticals, Inc. (SPI), USA, a wholly owned subsidiary of Senores Pharmaceuticals, announced that it has successfully entered into a strategic partnership by executing a formal operating agreement on 02 April 2026. This agreement marks a decisive milestone in Senores` international expansion and its strategic entry into the U.S. government procurement market. The partnership has been formalized through the formation of a joint venture (JV) entity, namely Amerisyn, LLC (Amerisyn).The partnership represents a structural leap for Senores` US operations. Through the establishment of this JV framework, Senores is now strategically positioned to facilitate the supply of its high-quality product portfolio to the U.S. Federal Government, veterans affairs and military supply contracts and leverage specialized credentials to participate in long-term national contracts and government supply tenders.

Net profit of Senores Pharmaceuticals rose 84.28% to Rs 31.66 crore in the quarter ended December 2025 as against Rs 17.18 crore during the previous quarter ended December 2024. Sales rose 60.02% to Rs 164.85 crore in the quarter ended December 2025 as against Rs 103.02 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales164.85103.02 60 OPM %32.7624.94 - PBDT52.4624.69 112 PBT44.6020.49 118 NP31.6617.18 84 Powered by Capital Market - Live News

Senores Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 20 January 2026.Powered by Capital Market - Live News

Senores Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 31 January 2026.Powered by Capital Market - Live News

Senores Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 January 2026.Powered by Capital Market - Live News